http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
-
Mirati Therapeutics (MRTX) Approved by the MHRA for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation MRTXas
-
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
-
Kura Oncology (KURA) and Mirati Therapeutics (MRTX) Enter Collaboration and Supply Agreement to for KO-2806 and Adagrasib in KRAS-Mutated NSCLC
-
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
-
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
-
Bristol Myers Squibb (BMY) to acquire Mirati Therapeutics (MRTX) for $58/share plus CVR
-
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
-
Mirati To Present Updated Clinical Data at ESMO Congress 2023
-
Mirati Therapeutics (MRTX) Presents Two-Year Follow-Up Data from KRYSTAL-1 Study
-
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
-
Mirati Therapeutics (MRTX) Announces CFO Departure
-
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
-
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
-
Mirati Therapeutics (MRTX) Reports Publication of Preclinical and Initial Clinical Data for MRTX1719
-
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
-
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
-
Mirati Therapeutics (MRTX) Announces CEO Departure
-
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
-
Mirati Therapeutics (MRTX) Provides Update on Regulatory Review in EU of KRAZATI
-
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
-
Mirati Therapeutics (MRTX) Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
-
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
-
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
-
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
-
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
-
Mirati Therapeutics (MRTX) Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO Does Not Meet Primary Endpoint
-
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
-
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
-
Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
-
Mirati Therapeutics (MRTX) Announces Publication of Updated Clinical Data for Adagrasib
-
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
-
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
-
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
-
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
-
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
-
Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference
-
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
-
Mirati Therapeutics (MRTX) Announces IND Clearance by U.S. FDA Enabling Phase 1 for KRASG12D
-
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
